Articles tagged with Bleeding
Researchers at University of British Columbia discovered that soil silicates can help control bleeding after injury by triggering clotting. The presence of soil in wounds activates a blood protein called coagulation Factor XII, leading to the formation of a plug and limiting blood loss.
A subgroup analysis from VOYAGER PAD found that adding clopidogrel to rivaroxaban and aspirin after lower extremity revascularization procedures did not provide any added clinical benefit for patients with peripheral artery disease. Instead, it increased the risk of bleeding events.
A randomized trial found that ticagrelor alone reduced major bleeding risk and no increased heart attacks, strokes, or other adverse events compared to dual therapy. The study suggests ticagrelor monotherapy as an optimal strategy for reducing bleeding risk in ACS patients treated with stents.
Patients with atrial fibrillation who took oral anticoagulants alone after TAVR had a lower rate of bleeding complications without an increased risk of clotting-related complications. Oral anticoagulants alone were significantly less likely to suffer bleeding complications than those who took antiplatelet medication in addition.
A subgroup of high-risk patients with complex heart disease who took ticagrelor alone had fewer episodes of bleeding and no increase in heart attacks or stroke. Ticagrelor monotherapy significantly reduced clinically relevant bleeding without increasing the risk of additional heart attacks, strokes or death.
People with symptomatic PAD who took rivaroxaban with aspirin after revascularization had a significant reduction in the composite primary endpoint, including acute limb ischemia, major amputation, heart attack, ischemic stroke or cardiovascular death. Rivaroxaban also showed no excess in severe bleeding events.
A study of patients with diabetes found that taking ticagrelor alone reduced clinically relevant bleeding compared to combining it with aspirin, without increasing the risk of additional heart attacks, strokes, or death. The results were consistent across all types of diabetes patients.
A new study found that Rivaroxaban significantly reduces the risk of venous thromboembolism (VTE) after lower limb orthopedic surgery by 75%, compared to heparin, without increasing the risk of bleeding. This breakthrough has significant implications for patients undergoing non-major orthopedic surgeries.
A systematic review and meta-analysis found that dual therapy with a direct oral anticoagulant (DOAC) plus P2Y12 inhibitor was associated with reduced risk of major bleeding compared to triple therapy with a vitamin K antagonist (VKA) plus aspirin and P2Y12 inhibitor for patients with nonvalvular atrial fibrillation after percutaneous ...
A nationwide prospective cohort study found that adults taking Vitamin K antagonist medication (VKA) had a lower incidence of overall bleeding events compared to direct oral anticoagulants. However, the VKA group also experienced a significantly higher mortality rate over one year.
A new study suggests that a common blood-clotting agent may be effective in treating bleeding stroke, with researchers noting a trend towards reduced hemorrhage expansion in patients treated promptly. Further trials are underway to confirm these findings and explore the potential for this treatment to enter routine clinical practice.
A new study suggests that mechanical clot removal alone may be as effective as combining it with IV clot-busters for treating acute strokes. The approach resulted in lower rates of brain bleeding and similar disability levels compared to the combination treatment.
A secondary analysis of the AUGUSTUS trial confirms that apixaban is safer than warfarin in patients with prior stroke or blood clot, while also reducing the risk of bleeding, hospitalization, and death. The study found that a strategy of apixaban plus a P2Y12 inhibitor without aspirin has the most favorable outcomes.
A study of 125,500 Danish patients with atrial fibrillation found that those who experienced bleeding were between 11 and 24 times more likely to be diagnosed with bowel cancer. Patients who had gastrointestinal bleeding should always be offered meticulous clinical examination regardless of anticoagulant treatment.
A new oral pill, elagolix, has been shown to effectively reduce heavy menstrual bleeding in women with uterine fibroids. The study found that 80.4% of women treated with elagolix alone experienced a 50% reduction in bleeding, compared to 9.6% in the placebo group.
A new study published in Neurology found that young black and Latino people are less likely to be disabled or die within three months after a hemorrhagic stroke. The study, which involved 418 participants, found significant differences in recovery rates among racial and ethnic groups.
Researchers have developed a superhydrophobic material that repels blood and promotes fast clotting, making it ideal for use as a bandage. The material's antibacterial effect also reduces the risk of infection when changing bandages.
A breakthrough gene therapy treatment has been shown to offer long-term benefits for people with Haemophilia A, transforming the lives of 13 UK patients. The treatment resulted in a substantial fall in bleeding rates three years after treatment, with none requiring regular factor VIII injections.
A new study suggests that taking aspirin daily to prevent a heart attack or stroke may no longer be recommended for adults without a history of these events. The study found that the potential benefits of aspirin are similar to its potential harms for most people, highlighting the need for personalized advice from doctors.
Scientists are testing a magnetically-actuated fluidic valve to reduce bleeding in trauma patients. The system uses an injectable magnetorheological suspension and externally placed magnets to create an obstruction, halting blood loss and stabilizing blood pressure. This could potentially extend survival time by at least 30 minutes.
A recent study found that tongue-tie procedures in babies can lead to respiratory events, bleeding, weight loss, and poor feeding. The researchers estimate that about 20 out of every 100,000 babies born will suffer a complication related to the procedure.
A study funded by NIH found that umbilical cord milking may increase the risk of severe intraventricular hemorrhage in extremely preterm infants. The study, halted due to safety concerns, compared cord milking to delayed cord clamping and found a higher rate of brain bleeding in the former group.
A programme of research and innovation led by Queen Mary University of London has reduced deaths from severe bleeding after major trauma by 40%. The 'Code Red' protocol, introduced between 2008 and 2017, involved new approaches to diagnosis and treatment, including the use of clotting components derived from blood.
Researchers discussed recent clinical study results comparing fibrinogen concentrate and cryoprecipitate in cardiac surgery, highlighting fibryga as a potential alternative for managing perioperative bleeding. The studies provide important data on fibryga's efficacy and safety in treating acquired fibrinogen deficiency.
Screening for ever-smokers with high lung cancer risk and long life-expectancy can prevent more deaths than current guidelines. A new study suggests using gains in life expectancy as a criterion to select candidates for screening, which could improve the balance of benefits and harms.
Researchers developed a neural network, PatchFCN, trained on 4,396 CT scans to detect brain hemorrhage abnormalities with accuracy similar to human experts. The algorithm achieved high accuracy and pixel-level delineation, classifying abnormalities into different pathological subtypes.
Researchers have discovered a protective protein called haptoglobin that prevents free hemoglobin from damaging neurons after brain hemorrhage. By administering purified haptoglobin directly into the cerebrospinal fluid, they were able to prevent vasospasms and block toxic effects.
A new AI algorithm developed by UCSF and UC Berkeley outperformed two out of four expert radiologists in detecting tiny brain hemorrhages on head scans. The algorithm achieved exam-level accuracy, tracing detailed outlines of abnormalities within the brain's three-dimensional structure.
A study shows that hyperbaric oxygen therapy can relieve self-reported symptoms and side-effects of radiotherapy in cancer patients, including bleeding, urinary incontinence, and pain. The treatment, administered for 30-40 sessions, was found to be highly effective for the majority of patients.
A global trial has found that early treatment with tranexamic acid can reduce deaths from traumatic brain injuries by up to 20%, depending on the severity of injury. The study, published in The Lancet, included over 12,000 patients and showed a significant benefit in those with mild and moderate injuries.
Researchers have identified a new disease mechanism and potential molecular drug target to protect premature newborns from developing post-hemorrhagic hydrocephalus. Treating mice with compounds blocking the LPA receptor prevented excess fluid accumulation in the brain.
New research warns Canadians against taking daily aspirin for primary prevention due to increased risk of major internal bleeding and potential increase in cancer deaths. Experts recommend alternative preventive measures such as smoking cessation, exercise, blood pressure tracking, and considering the Mediterranean diet.
A recent study published in JAMA Neurology found that postpartum women experiencing headaches from anesthesia after neuraxial anesthesia during childbirth are at a higher risk of being diagnosed with intracranial subdural hematoma. The study suggests a potential association between these two conditions.
A study by Loyola Medicine researchers found that pharmacist presence in the ER speeds up delivery of coagulation drug, improving patient outcomes. Patients with a bedside pharmacist spent less time in ICU (2 days vs. 5 days) and hospital overall (5.5 days vs. 8 days).
The THEMIS trial found that ticagrelor, when added to aspirin, reduced the risk of cardiovascular death, heart attack, or stroke by 10% in patients with stable coronary artery disease and diabetes. However, patients taking dual antiplatelet therapy also experienced a greater risk of major bleeding.
Research finds that patients experiencing internal bleeding after a heart attack may be at higher risk of developing cancer. The study suggests that early detection of bleeding can lead to improved cancer prognosis.
Researchers discovered that tryptase enzyme causes blood vessel leakage in severe dengue, leading to shock and bleeding. A possible new treatment strategy using nafamostat mesylate is being explored to prevent hemorrhaging and reverse shock.
A 72-year-old man experienced considerable pain, bleeding, and swallowing difficulties after his dentures got stuck in his throat during surgery. Despite multiple hospital visits and surgeries, he eventually recovered without further complications. The case highlights the importance of removing false teeth before general anesthetic.
Researchers at Waseda University developed a new nanoparticle combination therapy that effectively resuscitates trauma patients with massive hemorrhage. The therapy, using nanoparticles with hemostatic and oxygen-carrying potential, shows comparable results to conventional transfusion.
A large international study found that only 0.7% of deaths in noncardiac surgery patients occurred during the operating room period, while 29% occurred after discharge. Major bleeding, heart injury, and severe infection accounted for a significant portion of deaths.
Researchers found that cold snare polypectomy with continuous anticoagulant use does not increase bleeding risk, showing non-inferiority and even superiority over traditional methods. The study suggests that this procedure can be a safer alternative for patients taking blood thinners.
A Danish study of 32,000 haematological cancer patients found that one in five suffer from blood clots or bleeding, with varying risk levels depending on the type of cancer. The research highlights the need for individualized treatment and awareness of high-risk patients to prevent complications.
A new study found that biomedical bleeding can reduce spawning activity and alter biological rhythms in female horseshoe crabs, potentially impacting reproduction and population levels. The research suggests that the recovery from bleeding may also affect energy allocation towards spawning.
Researchers have identified patients more likely to have treatable underlying lesions from brain-bleeds, allowing for faster treatment. The study found that patients over 85 were unlikely to have a treatable lesion, while those under 50 had a 37% chance of finding a structural lesion.
Researchers created a nanoscale bioabsorbable wound dressing using chitosan, which shows promise in reducing blood loss and improving hemostasis. The dressing can be applied, left in the injury site, and eliminates the need for subsequent physical removal.
A University of Colorado study found that young-onset patients with colorectal cancer often experience prolonged rectal bleeding before diagnosis, leading to advanced stage cancer at the time of diagnosis. The average delay between symptom onset and diagnosis was 294 days.
The Saranas Early Bird Bleed Monitoring System has been shown to detect bleeding events during endovascular procedures with a high degree of accuracy, reducing the risk of complications and mortality. The device was tested in 60 patients and detected bleeding in 63% of cases, with no device-related complications reported.
The BRAVO-3 clinical trial found ProGlide VCD to be associated with lower rates of vascular complications and shorter hospitalizations after TAVR. The study showed ProGlide offered fewer complications compared to ProStar XL, with lower rates of acute kidney injury.
A new registry study finds that clinicians and patients have different perceptions of atrial fibrillation risk, leading to inconsistent treatment decisions. The AVIATOR 2 registry shows the need for better tools to quantify risk and improve patient outcomes.
A team of Lehigh University researchers characterized the shear-induced extensional response of vWF, revealing new insights into the protein's biomechanical behavior. They also developed a coarse-grained model to explain the protein's flow-induced properties, shedding light on its role in blood clotting and platelet function.
A systematic review of 631 pregnant women with Marfan Syndrome found an estimated 5.3% prevalence of acute aortic dissections during or after pregnancy. Conservative management with beta-blockers is recommended for type B dissections, while emergency surgical intervention is indicated for type A dissections.
A new experimental compound inhibits clot formation without raising the risk of bleeding, providing an effective and safer alternative to current therapies. The study found that the drug is well-tolerated at high doses and has a rapid, specific, and reversible action on platelets.
Researchers found threshold levels of circulating factor VIIa that prevented bleeding episodes in animal models, potentially leading to a new preventive treatment for patients with hemophilia who develop antibodies to standard maintenance therapy.
A new study has found that women with low-density lipoprotein (LDL) cholesterol levels below 70 mg/dL may be at a higher risk of hemorrhagic stroke. The study also found that women with the lowest triglyceride levels had an increased risk of bleeding strokes compared to those with the highest triglyceride levels.
A study published in EClinicalMedicine found that preterm babies born without the haptoglobin protein have a higher risk of brain bleeding, cerebral palsy, and death. The absence of the protein may serve as a potential biomarker for increased monitoring or preventive interventions.
Researchers found that ticagrelor has comparable efficacy to clopidogrel in patients treated with clot busters for a heart attack. The trial also showed that ticagrelor is safe for use in this patient population, with low rates of major bleeding.
Patients who stopped taking aspirin and continued clopidogrel fared significantly better after one year, with a reduced risk of bleeding and no increase in clot-related events. The study suggests that stopping DAPT after one month may be a good option for patients after drug-eluting stent implantation.
Patients treated with apixaban and a P2Y12 inhibitor had lower rates of bleeding and no increase in heart attacks or strokes compared to those receiving warfarin and aspirin. The combination reduced the risk of major bleeding by up to 47% without increasing mortality or hospitalization.
The HeartMate 3 left ventricular assist device (LVAD) significantly reduces strokes, pump-related blood clots, and bleeding episodes compared to the older HeartMate II. This trial enrolled 1,028 patients with advanced heart failure, showing a 40% reduction in risk favoring the HeartMate 3.
Patients who stopped taking aspirin three months after receiving a stent had a significantly lower rate of bleeding and no higher rate of death from any cause, heart attack, or stroke compared to those following standard therapy. The study's results balance ischemic and bleeding risks in patients undergoing PCI.